Solventum Corporation
SOLV | NYSE
$88.84
$0 (0.00%)
At close: Sep 21, 2026, 4:00 PM ET
$88.50
-$0.34 (-0.38%)
Pre-market:
Sep 22, 2026, 4:47 AM ET
Company Profile
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
Key Executives
| Name | Position |
|---|---|
| Bryan C. Hanson | Chief Executive Officer & Director |
| Amy Landucci | Chief Information & Digital Officer |
| Amy Wakeham | Senior Vice President of Investor Relations & External Finance Communications |
| Heather L. Knight | Chief Commercial Officer |
| Kate Dobbs | Chief Communications & Corporate Marketing Officer |
| Marcela A. Kirberger | Chief Corporate & Legal Affairs Officer & Corporate Secretary |
| Mary T. Wilcox | Senior Vice President, Corporate Controller & Chief Accounting Officer |
| Neil C. Zieselman | Senior VP, Controller & Chief Accounting Officer |
| Paul S. Harrington | Chief Supply Chain Officer |
| Rachel H. Ellingson | Chief Strategy & Corporate Development Officer |
| Tammy L. Gomez | Chief Human Resources Officer |
| Wayde D. McMillan | Executive VP & CFO |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 3 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 20, 2026 | 8-K | Current Report |
| Jun 05, 2026 | 8-K | Current Report |
| May 29, 2026 | SD | Filing |
| May 27, 2026 | 8-K | Current Report |
Solventum Corporation
| Country | United States |
| IPO Date | Mar 31, 2024 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 20,584 |
| CEO | Bryan C. Hanson |
Contact Details
1750 Yankee Doodle Road Eagan,
Minnesota 55121 United States
Stock Details
| Ticker Symbol | SOLV |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001964738 |
| CUSIP Number | 83444M101 |
| ISIN Number | US83444M1018 |
| SIC Code | 3841 |
Recent News
- 4 days ago / seekingalpha.comSolventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play
- 4 days ago / zacks.comHere's Why You Should Hold Solventum Stock in Your Portfolio for Now
- 4 days ago / zacks.comHere's Why Solventum (SOLV) is a Strong Value Stock
- 6 days ago / zacks.comWhy Solventum (SOLV) is a Top Stock for the Long-Term
- 13 days ago / seekingalpha.comSolventum Corporation (SOLV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
- 18 days ago / zacks.comSolventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
- 20 days ago / prnewswire.comSolventum to Participate in the 2026 Wells Fargo Healthcare Conference
- 20 days ago / zacks.comShould Investors Buy SOLV as Growth Improves but Debt Risks Persist?
- 20 days ago / zacks.comEarnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch
- 20 days ago / defenseworld.netSolventum Corporation (NYSE:SOLV) Receives Average Recommendation of “Moderate Buy” from Brokerages
Add to Watchlist
Select watchlists to add or remove SOLV